WELLESLEY HILLS, Mass., May 1 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM), a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products using its various drug delivery technologies, will present at the BIO Annual International Convention on May 8, 2007 at 4:00 pm in room D of the Business Forum at the Annual International Convention of the Biotechnology Industry Organization (BIO 2007) to be held at the Boston Convention and Exhibit Center. In his presentation, Robert J. DeLuccia, President and Chief Executive Officer of MacroChem, will provide an update on MacroChem's progress and future business strategy. In addition, the Company will join approximately 100 other Massachusetts companies and organizations with an exhibit (Booth # 533/A15) at the Massachusetts Pavilion.
This global event for biotechnology will draw more than 20,000 industry attendees, as well as 300 public officials from more than 30 countries, and will host more than 1,800 exhibiting companies for four days, showcasing the biotechnology industry and its global impact. The BIO Business Forum held May 7-9, 2007 is expected to host more than 10,000 partnering meetings and is sponsored by the Biotechnology Industry Organization (BIO), the 15th annual international convention.
About the Massachusetts Biotechnology Council
The Massachusetts Biotechnology Council (MBC), founded in 1985, is a not- for-profit trade organization that provides services and support for the Massachusetts biotechnology industry. The MBC is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 500 companies, academic institutions and service organizations involved in life sciences, the MBC works with public leaders to advance policy and promote education, while providing programs for its members.
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Currently, our portfolio of proprietary product candidates is based on our drug delivery technologies: SEPA(R), MacroDerm(TM) and DermaPass(TM). Our lead product candidate is EcoNail(TM), a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. In addition to EcoNail and Opterone, our pipeline of early-stage product candidates is based on our SEPA, MacroDerm and DermaPass drug delivery technologies. For more information visit our website, http://www.macrochem.com .
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled 'Risk Factors' in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com .
Contact:
MacroChem Corp.:
Bernard Patriacca - VP/CFO
(781) 489-7310
Investor Relations:
The Investor Relations Group, Inc.
Jordan Silverstein/Christine Berni
(212) 825-3210
SOURCE MacroChem Corporation
